Research showed that PPARG antagonists could abnormally activate the PI3K/AKT/mTOR and ERK/mTOR pathways in osteosarcoma cells and effectively inhibited the growth of OS in vivo and in vitro (Yuan et al., 2023). Here, MTOR is linked to osteosarcoma.